enow.com Web Search

  1. Ad

    related to: castration resistant cancer prognosis life expectancy

Search results

  1. Results from the WOW.Com Content Network
  2. Prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Prostate_cancer

    Prostate cancer is the second-most frequently diagnosed cancer in men, and the second-most frequent cause of cancer death in men (after lung cancer). [ 2 ] [ 3 ] Around 1.2 million new cases of prostate cancer are diagnosed each year, and over 350,000 people die of the disease, annually. [ 2 ]

  3. Management of prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Management_of_prostate_cancer

    This combination likely improves overall and cancer-specific survival by slowing the spread of the cancer. However, taxane-based chemotherapy may cause an increase in side effects. [45] Medications that block the production of adrenal androgens such as DHEA include ketoconazole and aminoglutethimide. Because the adrenal glands make only about 5 ...

  4. Darolutamide - Wikipedia

    en.wikipedia.org/wiki/Darolutamide

    Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. [8] [4] [5] [9] [10] It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. [4]

  5. Enzalutamide - Wikipedia

    en.wikipedia.org/wiki/Enzalutamide

    Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...

  6. Lutetium (177Lu) vipivotide tetraxetan - Wikipedia

    en.wikipedia.org/wiki/Lutetium_(177Lu)_vipivot...

    Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]

  7. Androgen deprivation therapy - Wikipedia

    en.wikipedia.org/wiki/Androgen_deprivation_therapy

    Cancer Stem Cell phenotypes are associated with disease recurrence, metastasis, and cell survival in circulation as Circulating tumor cells. Thus, activation of these programs via inhibition of the androgen axis provides a mechanism by which tumor cells can adapt to promote disease recurrence and progression.

  8. Cancer survival rates - Wikipedia

    en.wikipedia.org/wiki/Cancer_survival_rates

    The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3]

  9. Satraplatin - Wikipedia

    en.wikipedia.org/wiki/Satraplatin

    Satraplatin has been developed for the treatment of men with castrate-refractory, metastatic prostate cancer for several reasons. Its relative ease of administration, potential lack of cross-resistance with other platinum agents, clinical benefits seen in early studies of prostate cancer, and an unmet need in this patient population after Docetaxel failure at that time.

  1. Ad

    related to: castration resistant cancer prognosis life expectancy